HAEMONETICS CORP/MASS (HAE:NYSE)
$76.19 1.19 (1.5867%)
Analysed HAEMONETICS CORP/MASS (HAE:NYSE) News Sources
John Slump Launches Metis MedTech Following Atraverse Medical Acquisition by Johnson & Johnson
28-05-2026
yahoo.com
Haemonetics to Present at Goldman Sachs 47th Annual Global Healthcare Conference
02-06-2026
yahoo.com
Haemonetics Updates Financial Reporting Segments
05-06-2026
yahoo.com
Sector Update: Healthcare Stocks Higher Late Afternoon
05-06-2026
yahoo.com
A Look At Haemonetics (HAE) Valuation After Its New Apheresis And MedSurg Segment Realignment
09-06-2026
yahoo.com
[Latest] Global Therapeutic Apheresis Market Size/Share Worth USD 8.94 Billion by 2035 at a 7.9% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)
25-06-2026
yahoo.com
3 Profitable Stocks We Find Risky
26-06-2026
yahoo.com
3 Reasons HAE is Risky and 1 Stock to Buy Instead
30-06-2026
yahoo.com
Is it Apt to Retain Haemonetics Stock in Your Portfolio for Now?
03-07-2026
yahoo.com
Haemonetics Sets Date for Publishing First Quarter Fiscal Year 2027 Results: August 6, 2026
08-07-2026
yahoo.com
What is the current price of HAEMONETICS CORP/MASS (HAE:NYSE)?
The current price of HAEMONETICS CORP/MASS (HAE:NYSE) is $76.19.
HAEMONETICS CORP/MASS (HAE:NYSE) absolute price change since previous trading day?
The absolute price change of HAEMONETICS CORP/MASS (HAE:NYSE) since the previous trading day is $1.19.
HAEMONETICS CORP/MASS (HAE:NYSE) percentage price change since previous trading day?
The percentage price change of HAEMONETICS CORP/MASS (HAE:NYSE) since the previous trading day is 1.5867%.
What is the most recent average sentiment score for HAEMONETICS CORP/MASS (HAE:NYSE)?
The most recent average sentiment score for HAEMONETICS CORP/MASS (HAE:NYSE) is 58 out of 100.
What is the most recent average sentiment for HAEMONETICS CORP/MASS (HAE:NYSE)?
The most recent sentiment for HAEMONETICS CORP/MASS (HAE:NYSE) is .
SEC-8K** Filing Available For HAEMONETICS CORP/MASS (HAE:NYSE)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.